Tvardi Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	11.44	31.61	22.92	21.49
Short-Term Investments	10.87	-	-	22.25
Cash & Short-Term Investments	22.31	31.61	22.92	43.74
Cash Growth	-48.99%	37.94%	-47.60%	-
Prepaid Expenses	1.15	0.07	3.24	0.37
Total Current Assets	23.46	31.69	26.16	44.11
Property, Plant & Equipment	0.28	0.3	0.38	0.46
Other Intangible Assets	0.37	0.39	0.45	0.51
Long-Term Deferred Charges	3.69	2.81	-	-
Other Long-Term Assets	0.02	0.02	0.02	0.02
Total Assets	27.81	35.2	27	45.1
Accounts Payable	1.69	2.19	1.61	2.41
Accrued Expenses	5.21	8.08	1.58	1.79
Current Portion of Leases	0.11	0.1	0.09	0.08
Total Current Liabilities	7	10.37	3.28	4.28
Long-Term Debt	35.76	30.26	-	-
Long-Term Leases	0.17	0.2	0.28	0.37
Total Liabilities	42.93	40.83	3.56	4.65
Common Stock	0.02	0.02	0.02	0.02
Additional Paid-In Capital	1.17	1.09	0.76	0.45
Retained Earnings	-101.82	-92.24	-62.84	-45.49
Comprehensive Income & Other	0	-	-	-0.02
Total Common Equity	-100.63	-91.13	-62.06	-45.05
Shareholders' Equity	-15.12	-5.63	23.45	40.45
Total Liabilities & Equity	27.81	35.2	27	45.1
Total Debt	36.04	30.56	0.37	0.45
Net Cash (Debt)	-13.73	1.05	22.55	43.29
Net Cash Growth	-	-95.34%	-47.91%	-
Net Cash Per Share	-2.15	0.16	3.54	6.79
Filing Date Shares Outstanding	9.36	6.4	6.38	6.37
Total Common Shares Outstanding	6.4	6.4	6.38	6.37
Working Capital	16.46	21.32	22.88	39.83
Book Value Per Share	-15.72	-14.24	-9.73	-7.07
Tangible Book Value	-100.99	-91.52	-62.51	-45.56
Tangible Book Value Per Share	-15.78	-14.30	-9.80	-7.15

Source: S&P Global Market Intelligence. Standard template. Financial Sources.